MHB018A clinical trials
Also written MHB018A.
How each study uses MHB018A is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MHB018A studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2026 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 2 in phase 3
Studies that test MHB018A, phase 3 first.
- Dec 2026MHB018A Treatment in Patients With Active Thyroid Eye DiseasePhase 3 · Minghui Pharmaceutical (Hangzhou) Ltd
- Aug 2027MHB018A Treatment in Patients With Chronic Thyroid Eye DiseasePhase 3 · Minghui Pharmaceutical (Hangzhou) Ltd
Studies
Open first, then newest update. How each study uses MHB018A is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled StudyRecruitingPhase 3Minghui Pharmaceutical (Hangzhou) LtdNCT07622108Written as MHB018A
- Treatment of Chronic Thyroid Eye Disease With MHB018ARecruitingPhase 3Minghui Pharmaceutical (Hangzhou) LtdNCT07622121Written as MHB018A injection
- Open-Label Extension Study of MHB018A in Patients With Thyroid Eye DiseaseNot yet recruitingPhase 3Minghui Pharmaceutical (Hangzhou) LtdNCT07620405Written as MHB018A injection
- Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye DiseaseRecruitingPhase 3Minghui Pharmaceutical (Hangzhou) LtdNCT07262476Written as MHB018A injection
- MHB018A Treatment in Patients With Active Thyroid Eye DiseaseActive, not recruitingPhase 3Minghui Pharmaceutical (Hangzhou) LtdNCT06989918Written as MHB018A
- MHB018A Treatment in Patients With Chronic Thyroid Eye DiseaseActive, not recruitingPhase 3Minghui Pharmaceutical (Hangzhou) LtdNCT07257185Written as MHB018A injection